retatrutide and cancer & Pancreatic Research VisualAbstract: Improved Outcomes with Enzalutamide

R., Malnic, G

Nature Metabolism, 3, 142148

2023;325(5):E595-e609

"For several years now, we've had a strategy to talk to our customers about treating people as people, not as diseases, realizing that, unfortunately, they have multiple conditions or diseases going on at one time, and that multiprogram platform approach has allowed us to actually sell more programs into a single customer." Omada Health, which went public in June, also tightened the bottom line, reducing its net loss to $3 million, or an adjusted loss of 6 cents per share, compared to a loss of $9 million in the third quarter of 2024

Development 124 , 925936 (1997)